Concepedia

Kevin Laubscher

KL

12

Publications

974

Citations

11

H-Index

1994

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

Royal Marsden Hospital

The Barbara Ann Karmanos Cancer Institute

Indiana University – Purdue University Indianapolis

Kevin Laubscher is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

1994–2024

12

Publications

12

Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma

Toni K. Choueiri, Ulka N. Vaishampayan, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2012 · 455 citations · Full text

A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma

Ahmad A. Tarhini, Michael Millward, Paul N. Mainwaring et al. · Cancer · 2009 · 120 citations

The Clinical Course of Treated and Untreated Gaucher Disease. A Study of 45 Patients

Ernest Beutler, Anna Demina, Kevin Laubscher et al. · Blood Cells Molecules and Diseases · 1995 · 111 citations

, , +2

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

Brian C. Goh, Nandi J. Reddy, Uday B. Dandamudi et al. · Clinical Pharmacology & Therapeutics · 2010 · 82 citations

Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma

Matthew S. Davids, Amanda Charlton, Swee-Siang Ng et al. · Journal of Clinical Oncology · 2009 · 81 citations

Rows per page

1–5 of 12